Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.

Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol. 2019 12 10; 37(35):3446-3454.

View in: PubMed

subject areas

Adolescent
Adult
Angiogenesis Inhibitors
Bevacizumab
Biomarkers, Tumor
Child
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Induction Chemotherapy
Male
Middle Aged
Neurofibromatosis 2
Neuroma, Acoustic
Prognosis
Prospective Studies
Survival Rate
Young Adult

authors with profiles

James Howard Tonsgard